CLENBUTEROL

Details

Stereochemistry	RACEMIC
Molecular Formula	C12H18Cl2N2O
Molecular Weight	277.19
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1

InChI

InChIKey=STJMRWALKKWQGH-UHFFFAOYSA-N

InChI=1S/C12H18Cl2N2O/c1-12(2,3)16-6-10(17)7-4-8(13)11(15)9(14)5-7/h4-5,10,16-17H,6,15H2,1-3H3

HIDE SMILES / InChI

Description
Sources: http://rmtcnet.com/wp-content/uploads/2015/07/RMTC-Position-Paper-on-Clenbuterol.pdf
Curator's Comment: description was created based on several sources, including https://www.deadiversion.usdoj.gov/drug_chem_info/clenbuterol.pdf

Clenbuterol is agonist of beta2 adrenergic receptor. In some countries it is used as bronchodilator for treatment of asthma, but is not approved in USA. The drug is abused by bodybuilders and athletes for its ability to increase lean muscle mass and to reduce body fat. In 1998 FDA approved the clenbuterol-based Ventipulmin Syrup as a prescription-only drug for treatment of airway obstruction in horses.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Beta-2 adrenergic receptor 203 Target ID: CHEMBL210 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19245211	Agonist 2678		570.0 nM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Asthma 241 Sources: https://www.rlsnet.ru/tn_index_id_1750.htm	Primary		Approved 8429	SPIROPENT Approved Use Treatment of asthma, chroncic obstructive bronchitis, emphysema and other diseases.
Chronic obstructive pulmonary disease 174 Sources: https://www.rlsnet.ru/tn_index_id_1750.htm	Primary		Approved 8429	CLENBUTEROL Approved Use Treatment of asthma, chroncic obstructive bronchitis, emphysema and other diseases.

PubMed

Title	Date	PubMed
[Novel quantitative assessment of the tremorogenic effects of the beta 2-mimetics clenbuterol and salbutamol after oral administration].	1985	3907640
Clenbuterol and anabolic steroids: a previously unreported cause of myocardial infarction with normal coronary arteriograms.	1998 Aug	9715231
[Enantiomeric resolution of clenbuterol hydrochloride using (2R, 3R)-Dicyclohexyl tartrate impregnated thin layer chromatography].	2005 Nov	16499011
[Use of ultrasensitive time-resolved fluoroimmunoassay for rapid detection of clenbuterol hydrochloride in urine].	2006 Nov	17290771
Solid substrate-room temperature phosphorimetry for the determination of residual clenbuterol hydrochloride based on the catalysis of sodium periodate oxidizing eosine Y.	2009 Apr 6	19298881
Accumulation of the beta(2)-adrenergic agonist clenbuterol in mouse dark hair.	2009 Nov	19533101
Beta2-adrenergic agonist-induced hypertrophy of the quadriceps skeletal muscle does not modulate disease severity in the rodent meniscectomy model of osteoarthritis.	2010 Apr	20060953

Patents

Sample Use Guides

In Vivo Use Guide

For treatmen of airways obstruction the clenbuterol is administered orally, 15ml of syrop 2-3 times a day.

Route of Administration: Oral

In Vitro Use Guide

Affinity towards beta2 adrenergic receptors was measured using the recombinant receptor expressed in Sf-9 cells. Cell membrane homogenates were incubated with 0.15 nM of radioligand [3H]CGP1217 in the absence of presence of the clenbuterol. Following incubation, the samples were filtered rapidly under vacuum through through glass fiber filters, the filters were dried, and counted for radioactivity in a scintillation counter. Clenbuterol was binding to beta2 receptor with Ki of 0.58 uM.

Name

Type

Language

CLENBUTEROL

Official Name

English

CLENBUTEROL [MI]

Common Name

English

Clenbuterol [WHO-DD]

Common Name

English

clenbuterol [INN]

Common Name

English

PLANIPART

Brand Name

English

NAB 365

Code

English

CONTRASPASMIN

Brand Name

English

NSC-758633

Code

English

Classification Tree Code System Code

WHO-VATC

QR03CC13